Edgewise Therapeutics, Inc. (EWTX)

Market Cap	2.91B
Revenue (ttm)	n/a
Net Income (ttm)	-124.29M
Shares Out	94.69M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	824,670
Open	30.54
Previous Close	30.80
Day's Range	30.06 - 32.61
52-Week Range	9.00 - 38.12
Beta	0.13
Analysts	Buy
Price Target	44.83 (+45.65%)
Earnings Date	Feb 20, 2025

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 88
• Stock Exchange: NASDAQ
• Ticker Symbol: EWTX
• Website: https://www.edgewisetx.com

Analyst Forecast

According to 6 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is $44.83, which is an increase of 45.65% from the latest price.

Price Target

$44.83

(45.65% upside)

Analyst Consensus: Buy